BRPI1006748A2 - método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica - Google Patents

método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica

Info

Publication number: BRPI1006748A2
Authority: BR; Brazil
Prior art keywords: vip; prophylactic; individual; therapeutic treatment; vasoactive intestinal
Prior art date: 2009-04-02

Application number

BRPI1006748A

Other languages

English (en)

Inventor

Annette Duggan Karen

Original Assignee

Vectus Biosystems Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-02

Filing date

2010-04-06

Publication date

2018-03-06

2009-04-02 Priority claimed from AU2009901425A external-priority patent/AU2009901425A0/en

2010-04-06 Application filed by Vectus Biosystems Pty Ltd filed Critical Vectus Biosystems Pty Ltd

2018-03-06 Publication of BRPI1006748A2 publication Critical patent/BRPI1006748A2/pt

Links

VBUWHHLIZKOSMS-KDPLEQQTSA-N dnc009566 Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)C(C)C)[C@@H](C)O)[C@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-KDPLEQQTSA-N 0.000 title 4
206010016654 Fibrosis Diseases 0.000 title 2
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 title 2
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 title 2
230000004761 fibrosis Effects 0.000 title 2
238000000034 method Methods 0.000 title 2
230000000069 prophylactic effect Effects 0.000 title 2
230000001225 therapeutic effect Effects 0.000 title 2
102000008186 Collagen Human genes 0.000 title 1
108010035532 Collagen Proteins 0.000 title 1
230000015572 biosynthetic process Effects 0.000 title 1
229920001436 collagen Polymers 0.000 title 1
230000011382 collagen catabolic process Effects 0.000 title 1
230000002708 enhancing effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

BRPI1006748A 2009-04-02 2010-04-06 método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica BRPI1006748A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AU2009901425A AU2009901425A0 (en)		2009-04-02	Compositions and methods for treatment of aortic fibrosis
PCT/AU2010/000391 WO2010111753A1 (en)	2009-04-02	2010-04-06	Compositions and methods for treatment of aortic fibrosis

Publications (1)

Publication Number	Publication Date
BRPI1006748A2 true BRPI1006748A2 (pt)	2018-03-06

Family

ID=42827427

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1006748A BRPI1006748A2 (pt)	2009-04-02	2010-04-06	método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica

Country Status (18)

Country	Link
US (2)	US8729020B2 (pt)
EP (1)	EP2413954B1 (pt)
JP (1)	JP5687266B2 (pt)
KR (1)	KR101627008B1 (pt)
CN (1)	CN102711797A (pt)
AU (1)	AU2010230862B2 (pt)
BR (1)	BRPI1006748A2 (pt)
CA (1)	CA2757076C (pt)
DK (1)	DK2413954T3 (pt)
ES (1)	ES2462501T3 (pt)
IL (1)	IL215460A (pt)
MX (1)	MX2011010341A (pt)
MY (1)	MY180681A (pt)
NZ (1)	NZ595726A (pt)
RU (1)	RU2536223C2 (pt)
SG (1)	SG174966A1 (pt)
WO (1)	WO2010111753A1 (pt)
ZA (1)	ZA201107820B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1976548E (pt)	2005-12-09	2014-10-13	Vectus Biosystems Ltd	Fragmentos de vip e suas composições
WO2010042997A1 (en) *	2008-10-17	2010-04-22	Vectus Biosystems Pty Limited	Compositions and methods for treatment of kidney disorders
EP2990027A1 (en) *	2014-09-01	2016-03-02	Institut Curie	Skin whitening peptide agents
CN104980999B (zh) *	2015-06-19	2017-03-08	广东欧珀移动通信有限公司	一种网络接入方法及移动终端
WO2024233903A1 (en) *	2023-05-11	2024-11-14	Wayne State University	Combination treatments to promote epithelial integrity and treat ocular disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040063631A1 (en)	2000-11-28	2004-04-01	Lutz-Henning Block	Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
DK1768689T3 (en) *	2004-06-11	2014-12-01	Vectus Biosystems Ltd	Compositions and methods for treating cardiovascular disease
PT1976548E (pt) *	2005-12-09	2014-10-13	Vectus Biosystems Ltd	Fragmentos de vip e suas composições
EP2188017A2 (en) *	2007-09-11	2010-05-26	Mondobiotech Laboratories AG	Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
WO2010042997A1 (en) *	2008-10-17	2010-04-22	Vectus Biosystems Pty Limited	Compositions and methods for treatment of kidney disorders

2010
- 2010-04-06 KR KR1020117025945A patent/KR101627008B1/ko not_active Expired - Fee Related
- 2010-04-06 MX MX2011010341A patent/MX2011010341A/es active IP Right Grant
- 2010-04-06 EP EP10757953.4A patent/EP2413954B1/en active Active
- 2010-04-06 DK DK10757953.4T patent/DK2413954T3/da active
- 2010-04-06 SG SG2011070778A patent/SG174966A1/en unknown
- 2010-04-06 US US13/262,064 patent/US8729020B2/en active Active
- 2010-04-06 JP JP2012502396A patent/JP5687266B2/ja not_active Expired - Fee Related
- 2010-04-06 WO PCT/AU2010/000391 patent/WO2010111753A1/en not_active Ceased
- 2010-04-06 NZ NZ595726A patent/NZ595726A/xx not_active IP Right Cessation
- 2010-04-06 RU RU2011142268/15A patent/RU2536223C2/ru active
- 2010-04-06 CN CN2011800017312A patent/CN102711797A/zh active Pending
- 2010-04-06 BR BRPI1006748A patent/BRPI1006748A2/pt not_active Application Discontinuation
- 2010-04-06 ES ES10757953.4T patent/ES2462501T3/es active Active
- 2010-04-06 AU AU2010230862A patent/AU2010230862B2/en not_active Ceased
- 2010-04-06 MY MYPI2011004649A patent/MY180681A/en unknown
- 2010-04-06 CA CA2757076A patent/CA2757076C/en active Active
2011
- 2011-10-02 IL IL215460A patent/IL215460A/en active IP Right Grant
- 2011-10-25 ZA ZA2011/07820A patent/ZA201107820B/en unknown
2014
- 2014-04-15 US US14/252,818 patent/US20140235541A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2010230862A1 (en)	2011-11-03
US20120027850A1 (en)	2012-02-02
DK2413954T3 (da)	2014-05-12
AU2010230862B2 (en)	2014-04-17
MX2011010341A (es)	2012-01-27
RU2011142268A (ru)	2013-05-10
MY180681A (en)	2020-12-06
HK1165271A1 (en)	2012-10-05
JP5687266B2 (ja)	2015-03-18
US8729020B2 (en)	2014-05-20
IL215460A0 (en)	2011-12-29
SG174966A1 (en)	2011-11-28
NZ595726A (en)	2013-06-28
CA2757076A1 (en)	2010-10-07
ZA201107820B (en)	2013-09-25
EP2413954A1 (en)	2012-02-08
JP2012522727A (ja)	2012-09-27
CA2757076C (en)	2017-05-16
RU2536223C2 (ru)	2014-12-20
KR101627008B1 (ko)	2016-06-02
WO2010111753A1 (en)	2010-10-07
ES2462501T3 (es)	2014-05-23
US20140235541A1 (en)	2014-08-21
CN102711797A (zh)	2012-10-03
KR20120024572A (ko)	2012-03-14
IL215460A (en)	2017-01-31
EP2413954A4 (en)	2012-11-21
EP2413954B1 (en)	2014-02-26

Similar Documents

Publication	Publication Date	Title
BR112012008854A2 (pt)	2015-09-22	combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
NO2017003I1 (no)	2017-01-12	Kobicistat eller farmasøytisk akseptabelt salt derav og tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat
ZA200901132B (en)	2010-10-27	Human GLP-1 mimetibodies, compositions, methods and uses
IL187982A0 (en)	2008-03-20	Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
BRPI0809655A2 (pt)	2014-10-07	Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
IL196965A0 (en)	2009-11-18	Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure
BRPI0815850A2 (pt)	2014-10-07	"método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico"
BR112013019083A2 (pt)	2017-04-04	combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
BRPI0816934A2 (pt)	2015-03-17	Estimulador da musculatura facial e bucal
EP1723804A4 (en)	2011-09-07	MOBILITY ARCHITECTURE BASED ON THE USE OF PRE-AUTHENTICATION, PRE-CONFIGURATION AND / OR INTERCELLULAR TRANSFER WITHOUT VIRTUAL BREAK
MX2010008206A (es)	2010-08-10	Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
ZA201001189B (en)	2010-11-24	Treatments using vitamin k analogues and derivatives
BRPI0809663A2 (pt)	2014-10-14	Composição de vírus vivo atenuado, método de diminuição da inativação de composição de vírus vivo atenuado e kit respectivo
SI1971366T1 (sl)	2014-10-30	Humana protitelesa anti-il-23, sestavki, postopki in uporabe
EP2058014A4 (en)	2012-10-24	ARTIFICIAL BONE ASSOCIATION
HUE038026T2 (hu)	2018-09-28	Csontcement kompozíció, csontcement kompozíció készlet, és eljárás csontcementtel gyógyított test kialakítására
IL219318A0 (en)	2012-06-28	Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
BRPI0912292A2 (pt)	2015-10-20	composições e métodos para o uso de células no tratamento do tecido cardíaco.
EP2234625B8 (en)	2013-10-30	Compositions and methods for treating and preventing skeletal muscle deficiencies
BRPI1006748A2 (pt)	2018-03-06	método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica
BRPI0813423A2 (pt)	2014-12-23	Uso de uma composição, e, composição nutricional para a estimulação de uma flora intestinal saudável em pacientes com hiv
EP2427167A4 (en)	2012-12-19	METHOD AND COMPOSITION FOR RECOVERING AGED-INFUSED TISSUE LOSS IN THE FACE OR PARTICULAR BODY RANGE
NZ592612A (en)	2013-01-25	Vasoactive intestinal peptide (VIP) Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-X for the treatment of kidney disorders
PT1991292T (pt)	2018-10-08	Kit para a regeneração de tecidos adiposos e respectivo método de utilização
MX2012001409A (es)	2012-05-23	Fragmento de agrina modificado capaz de restaurar la potencia muscular para utilizarse como un medicamento.

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-09	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.
2020-05-05	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-09-01	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-08-17	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-12-07	B09B	Patent application refused [chapter 9.2 patent gazette]
2022-02-22	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL